According to Zacks, “INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company’s product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States. “
Several other equities analysts also recently weighed in on INMB. Maxim Group raised their target price on INmune Bio from $32.00 to $42.00 and gave the company a buy rating in a research report on Wednesday, July 7th. B. Riley lifted their price objective on INmune Bio from $26.00 to $32.00 and gave the stock a buy rating in a research report on Tuesday, September 7th.
INmune Bio (NASDAQ:INMB) last posted its earnings results on Tuesday, August 3rd. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.10). Equities analysts expect that INmune Bio will post -1.7 EPS for the current year.
In other news, CFO David J. Moss sold 8,698 shares of the business’s stock in a transaction dated Wednesday, July 7th. The stock was sold at an average price of $20.01, for a total value of $174,046.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Timothy J. Schroeder sold 14,480 shares of the business’s stock in a transaction dated Tuesday, July 13th. The shares were sold at an average price of $27.63, for a total value of $400,082.40. The disclosure for this sale can be found here. Insiders have sold a total of 64,677 shares of company stock valued at $1,500,339 over the last ninety days. 53.90% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Morgan Stanley increased its position in INmune Bio by 273.2% in the 2nd quarter. Morgan Stanley now owns 11,543 shares of the company’s stock valued at $203,000 after acquiring an additional 8,450 shares during the period. Royal Bank of Canada increased its position in INmune Bio by 1.4% in the 2nd quarter. Royal Bank of Canada now owns 66,458 shares of the company’s stock valued at $1,168,000 after acquiring an additional 910 shares during the period. State Street Corp acquired a new position in INmune Bio in the 2nd quarter valued at about $612,000. Altium Capital Management LP acquired a new position in INmune Bio in the 2nd quarter valued at about $918,000. Finally, Geode Capital Management LLC increased its position in INmune Bio by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 73,794 shares of the company’s stock worth $1,296,000 after purchasing an additional 12,957 shares during the period. Hedge funds and other institutional investors own 9.76% of the company’s stock.
INmune Bio Company Profile
INmune Bio, Inc focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer’s disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
Read More: What is a good dividend yield?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.